Icaritin

Drug Profile

Icaritin

Alternative Names: IC-162; SNG 162

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shenogen Pharma
  • Developer Chinese Academy of Medical Sciences; Shenogen Pharma
  • Class
  • Mechanism of Action Estrogen receptor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Phase I Solid tumours
  • No development reported Breast cancer

Most Recent Events

  • 20 Nov 2017 Phase-III clinical trials in Hepatocellular carcinoma (Late-stage disease) in China (PO)
  • 21 Aug 2017 Shenogen Pharma initiates a phase I clinical trial in Healthy volunteers in China (ChiCTR-OIC17012454)
  • 07 Aug 2017 Beijing Shenogen Biomedical plans a phase III trial for Hepatocellular carcinoma (NCT03236636)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top